Radiomic models based on magnetic resonance imaging predict the spatial distribution of CD8+ tumor-infiltrating lymphocytes in breast cancer

被引:5
|
作者
Jeon, Seung Hyuck [1 ]
Kim, So-Woon [2 ]
Na, Kiyong [2 ]
Seo, Mirinae [3 ]
Sohn, Yu-Mee [3 ]
Lim, Yu Jin [4 ]
机构
[1] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon, South Korea
[2] Kyung Hee Univ Coll Med, Kyung Hee Univ Med Ctr, Dept Pathol, Seoul, South Korea
[3] Kyung Hee Univ Coll Med, Kyung Hee Univ Med Ctr, Dept Radiol, Seoul, South Korea
[4] Kyung Hee Univ Coll Med, Kyung Hee Univ Med Ctr, Dept Radiat Oncol, Seoul, South Korea
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
新加坡国家研究基金会;
关键词
immunophenotype; CD8+T cells; radiomics; breast cancer; magnetic resonanace imaging; CHEMOTHERAPY;
D O I
10.3389/fimmu.2022.1080048
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Infiltration of CD8(+) T cells and their spatial contexture, represented by immunophenotype, predict the prognosis and therapeutic response in breast cancer. However, a non-surgical method using radiomics to evaluate breast cancer immunophenotype has not been explored. Here, we assessed the CD8(+) T cell-based immunophenotype in patients with breast cancer undergoing upfront surgery (n = 182). We extracted radiomic features from the four phases of dynamic contrast-enhanced magnetic resonance imaging, and randomly divided the patients into training (n = 137) and validation (n = 45) cohorts. For predicting the immunophenotypes, radiomic models (RMs) that combined the four phases demonstrated superior performance to those derived from a single phase. For discriminating the inflamed tumor from the non-inflamed tumor, the feature-based combination model from the whole tumor (RM-whole(FC)) showed high performance in both training (area under the receiver operating characteristic curve [AUC] = 0.973) and validation cohorts (AUC = 0.985). Similarly, the feature-based combination model from the peripheral tumor (RM-peri(FC)) discriminated between immune-desert and excluded tumors with high performance in both training (AUC = 0.993) and validation cohorts (AUC = 0.984). Both RM-whole(FC) and RM-peri(FC) demonstrated good to excellent performance for every molecular subtype. Furthermore, in patients who underwent neoadjuvant chemotherapy (n = 64), pre-treatment images showed that tumors exhibiting complete response to neoadjuvant chemotherapy had significantly higher scores from RM-whole(FC) and lower scores from RM-peri(FC). Our RMs predicted the immunophenotype of breast cancer based on the spatial distribution of CD8(+) T cells with high accuracy. This approach can be used to stratify patients non-invasively based on the status of the tumor-immune microenvironment.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer
    Kayo Fukui
    Norio Masumoto
    Noriyuki Shiroma
    Akiko Kanou
    Shinsuke Sasada
    Akiko Emi
    Takayuki Kadoya
    Michiya Yokozaki
    Koji Arihiro
    Morihito Okada
    Breast Cancer, 2019, 26 : 573 - 580
  • [32] Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer
    Yun Liang
    Weiguo Lü
    Xiaofei Zhang
    Bingjian Lü
    Diagnostic Pathology, 13
  • [33] Magnetic Resonance Imaging of Tumor-Infiltrating Lymphocytes by Anti-CD3-Conjugated Iron Oxide Nanoparticles
    Pournoori, Negin
    Oghabian, Mohammad Ali
    Irajirad, Rasoul
    Muhammadnejad, Samad
    Delavari, Hamid H.
    CHEMMEDCHEM, 2022, 17 (11)
  • [34] Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response
    Rapoport, Bernardo Leon
    Nayler, Simon
    Mlecnik, Bernhard
    Smit, Teresa
    Heyman, Liezl
    Bouquet, Isabelle
    Martel, Marine
    Galon, Jerome
    Benn, Carol-Ann
    Anderson, Ronald
    CANCERS, 2022, 14 (10)
  • [35] Tumor-Associated Macrophages and Tumor-Infiltrating CD8+ Lymphocytes in Breast Cancer: Its Association with Epithlelial-Mesenchymal Transition and Breast Cancer Stem Cell Phenotype
    Choi, Y.
    Kim, D. I.
    Kim, E. J.
    Park, S. Y.
    MODERN PATHOLOGY, 2012, 25 : 29A - 29A
  • [36] Usefulness of imaging findings in predicting tumor-infiltrating lymphocytes in patients with breast cancer
    Filiz Çelebi
    Filiz Agacayak
    Alper Ozturk
    Serkan Ilgun
    Muhammed Ucuncu
    Zeynep Erdogan Iyigun
    Çetin Ordu
    Kezban Nur Pilanci
    Gul Alco
    Serap Gultekin
    Emetullah Cindil
    Gursel Soybir
    Fatma Aktepe
    Vahit Özmen
    European Radiology, 2020, 30 : 2049 - 2057
  • [37] Quantifying Spatial Heterogeneity of Tumor-Infiltrating Lymphocytes to Predict Survival of Individual Cancer Patients
    Suwalska, Aleksandra
    Zientek, Lukasz
    Polanska, Joanna
    Marczyk, Michal
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (07):
  • [38] Usefulness of imaging findings in predicting tumor-infiltrating lymphocytes in patients with breast cancer
    Celebi, Filiz
    Agacayak, Filiz
    Ozturk, Alper
    Ilgun, Serkan
    Ucuncu, Muhammed
    Iyigun, Zeynep Erdogan
    Ordu, Cetin
    Pilanci, Kezban Nur
    Alco, Gul
    Gultekin, Serap
    Cindil, Emetullah
    Soybir, Gursel
    Aktepe, Fatma
    Ozmen, Vahit
    EUROPEAN RADIOLOGY, 2020, 30 (04) : 2049 - 2057
  • [39] Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis
    Steele, Keith E.
    Tan, Tze Heng
    Korn, Rene
    Dacosta, Karma
    Brown, Charles
    Kuziora, Michael
    Zimmermann, Johannes
    Laffin, Brian
    Widmaier, Moritz
    Rognoni, Lorenz
    Cardenes, Ruben
    Schneider, Katrin
    Boutrin, Anmarie
    Martin, Philip
    Zha, Jiping
    Wiestler, Tobias
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [40] The Impact of Nutritional Status and Tumor-Infiltrating Lymphocytes (CD4+and CD8+) on Chemotherapy Response in Colorectal Cancer Patients
    Lukman, Kiki
    Septianto, Rhandy
    Rudiman, Reno
    Ruchimat, Tommy
    Sribudiani, Yunia
    Nugraha, Prapanca
    Primastari, Etis
    Budiman, Deny
    CANCER MANAGEMENT AND RESEARCH, 2025, 17 : 197 - 209